Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galactose SCHEMBL2964862 | 1.00 | PDE4A (0.38) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL2878983 | 0.94 | LMNA (0.39) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL27278309 | 0.94 | LMNA (0.39) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Demannose SCHEMBL1422978 | 0.93 | PDE4A (0.35) | PDE4ALMNAUSP2SLCO1B1CYP1A2 | |
| Galactose SCHEMBL31555927 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Galactose SCHEMBL423422 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Galactose SCHEMBL30458008 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL13277644 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL3630269 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Demannose SCHEMBL21456966 | 0.85 | PDE4A (0.50) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411111-B1 | LOW FOAMING DETERGENT COMPOSITIONS | SARAYA CO LTD (JP) | 2008-09-10 | — | — | EP | claimed |
| EP-4566549-A2 | OCCLUSION DEVICE FOR AN ATRIAL APPENDAGE | Boston Scientific Scimed, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4554953-A1 | MODIFIED SOPHOROLIPIDS WITH ENHANCED DEFOAMING PROPERTIES | Locus Solutions IPCO, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250154189-A1 | Modified Sophorolipids with Enhanced Defoaming Properties | LOCUS SOLUTIONS IPCO, LLC | 2025-05-15 | — | — | US | disclosed |
| EP-3900648-B1 | OCCLUSION DEVICE FOR AN ATRIAL APPENDAGE | BOSTON SCIENT SCIMED INC (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-3615646-B1 | BIODEGRADABLE CLEANING COMPOSITION | EVONIK OPERATIONS GMBH (DE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015844-A1 | MODIFIED SOPHOROLIPIDS WITH ENHANCED DEFOAMING PROPERTIES | LOCUS SOLUTIONS IPCO, LLC (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11746307-B2 | Biodegradable cleaning composition | EVONIK OPERATIONS GMBH (DE) | 2023-09-05 | — | — | US | disclosed |
| US-20230193157-A1 | BIODEGRADABLE CLEANING COMPOSITION | EVONIK OPERATIONS GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-11591547-B2 | Biodegradable cleaning composition | EVONIK OPERATIONS GMBH (DE) | 2023-02-28 | — | — | US | disclosed |
| EP-0325109-A2 | Sugar esters as detergency boosters | Colgate-Palmolive Company (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0325124-A2 | Sugar ethers as bleach stable detergency boosters | Colgate-Palmolive Company (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0325100-A2 | Acetylated sugar ethers as bleach activators and detergency boosters | Colgate-Palmolive Company (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0325184-A1 | Acetylated sugar ethers as bleach activators detergency boosters and fabric softener | Colgate-Palmolive Company (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4800038-A | HEAVY DUTY, NON-AQUEOUS | COLGATE-PALMOLIVE COMPANY (US) | 1989-01-24 | — | — | US | disclosed |
| EP-0095904-B1 | DETERGENT LIQUORS AND COMPOSITIONS FOR USE THEREIN | THE PROCTER & GAMBLE COMPANY (US) | 1986-09-03 | — | — | EP | disclosed |
| EP-0101113-B1 | DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 1986-05-28 | — | — | EP | disclosed |
| US-4547305-A | CONTAINING A SILICATE AND TITANIUM | LEVER BROTHERS COMPANY (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0101113-A1 | Detergent compositions | UNILEVER N.V. (NL) | 1984-02-22 | — | — | EP | disclosed |
| EP-0095904-A1 | Detergent liquors and compositions for use therein | THE PROCTER & GAMBLE COMPANY (US) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154189-A1 | Modified Sophorolipids with Enhanced Defoaming Properties | LIPA, MGLL, LPL | PDE4A 1477/4885LMNA 663/4885USP2 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.